Literature DB >> 306075

Abnormal T cell subpopulations and circulating immune complexes in the Guillain-Barré syndrome and multiple sclerosis.

J M Goust, F Chenais, J E Carnes, C G Hames, H H Fudenberg, E L Hogan.   

Abstract

Immunologic studies were performed in 21 patients with multiple sclerosis (MS) and 16 with the Guillain-Barré syndrome (GBS). Levels of thymus-derived (T) cells measured by "total" and "active" rosette formation between sheep erythrocytes and peripheral blood mononuclear cells (TEt, TEa) were within normal limits in all the patients, with the exception of four GBS patients, including one who also had received chemotherapy for lymphoma and three who were receiving steroids. When lymphocytes from the 21 patients were incubated with the bone-marrow-derived (B) lymphoblastoid cell line PGLC-33H, there were, for 12 of 18 MS patients and 11 of 16 GBS patients, significant decreases in a subpopulation of peripheral blood T lymphocytes that form "PGLC rosettes" (PGR) with the PGLC-33H cells. (Peripheral blood T cells from normal individuals formed PGR with 23.9 +/- 3.8 percent of PGLC-33H cells.) Using the 125l-C1q binding assay, immune complexes were detected in the serum of 14 of 19 MS patients and 15 of 16 GBS patients. An association between increased C1q binding and decreased PGR values was found in 10 of 18 MS patients and 12 of 17 GBS patients. The results suggest that in both diseases the etiology may involve a decrease in the subset of T cells that bind to the IgM-producing cell line PGLC-33H, in association with the appearance of circulating immune complexes containing the infectious viral agent.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 306075     DOI: 10.1212/wnl.28.5.421

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

1.  T-lymphocyte subsets modifications in multiple sclerosis: correlation with clinical disease activity.

Authors:  M Prencipe; E Salerni; C D'Aurizio; C Marini; D Adorno; A M Berghella; P Pellegrini; F Papola; C U Casciani
Journal:  Ital J Neurol Sci       Date:  1986-12

2.  A prospective study of acute idiopathic neuropathy. III. Immunological studies.

Authors:  J B Winer; I A Gray; N A Gregson; R A Hughes; S Leibowitz; P Shepherd; W A Taylor; V Yewdall
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-05       Impact factor: 10.154

3.  Immune complexes in CSF and serum in various neurological diseases.

Authors:  M Cavalli; E Merelli; P Sola; G Pirrò; P Faglioni
Journal:  Ital J Neurol Sci       Date:  1986-04

4.  Significance of lymphocytes and blood vessel changes for edema formation in polyradiculoneuritis.

Authors:  R J Seitz; E Neuen-Jacob; W Wechsler
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

Review 5.  Immunology of Guillain-Barré syndrome.

Authors:  I Steiner; O Abramsky
Journal:  Springer Semin Immunopathol       Date:  1985

6.  Heterogeneity of Alzheimer's disease. An interpretive review.

Authors:  H H Fudenberg
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590

7.  The influence of disease activity on the number of blood cells of multiple sclerosis patients.

Authors:  U Patzold; U Wurster; K Mardt; M Schiemann
Journal:  J Neurol       Date:  1984       Impact factor: 4.849

8.  The treatment of inflammatory polyneuropathy by plasma exchange.

Authors:  M L Gross; N J Legg; M C Lockwood; C Pallis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-08       Impact factor: 10.154

Review 9.  Guillain-Barré syndrome, transverse myelitis and infectious diseases.

Authors:  Yhojan Rodríguez; Manuel Rojas; Yovana Pacheco; Yeny Acosta-Ampudia; Carolina Ramírez-Santana; Diana M Monsalve; M Eric Gershwin; Juan-Manuel Anaya
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

10.  Clinical effects of plasmapheresis in acute Guillain-Barré syndrome.

Authors:  G Piccolo; V Cosi; M Lombardi; M Poloni; M Ceroni; P M Fornasari
Journal:  Ital J Neurol Sci       Date:  1986-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.